Related Experiment Video
Updated: Sep 29, 2025
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.2K
Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study
Nienke Brouwer1, Sergio Matarraz2,3, Stefan Nierkens4
1Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Cancers
|March 25, 2022
Summary
This study demonstrates that the EuroFlow AML panel effectively diagnoses acute megakaryoblastic leukemia (AMKL) by identifying key immunophenotypic markers. Down syndrome-associated leukemia exhibits a distinct profile, aiding in precise diagnosis.
Area of Science:
- Hematology
- Immunophenotyping
- Flow Cytometry
Background:
- Acute megakaryoblastic leukemia (AMKL) is a rare, heterogeneous subtype of acute myeloid leukemia (AML).
- Accurate immunophenotypic profiling is crucial for diagnosing AMKL subtypes, including transient abnormal myelopoiesis (TAM), myeloid leukemia associated with Down syndrome (ML-DS), and AML-not otherwise specified with megakaryocytic differentiation (NOS-AMKL).
Purpose of the Study:
- To evaluate the diagnostic utility of the EuroFlow AML panel for AMKL.
- To identify key immunophenotypic markers for distinguishing AMKL from other AML subtypes.
- To characterize the immunophenotypic profiles of different AMKL subgroups, particularly ML-DS.
Main Methods:
- Flow cytometric analysis of 72 AMKL and 114 non-AMKL AML patients using the EuroFlow AML panel.
- Univariate, multivariate, and multidimensional analyses to identify diagnostic markers.
- Subgrouping of AMKL patients into TAM, ML-DS, NOS-AMKL, and AMKL-other categories.
Main Results:
- The EuroFlow AML panel effectively discriminated AMKL from non-AMKL using markers like CD42a.CD61, CD41, CD42b, HLADR, CD15, and CD13.
- A combination of CD42a.CD61 (positive) and CD13 (negative) achieved 71% sensitivity and 99% specificity for AMKL diagnosis.
- TAM and ML-DS subgroups showed higher frequencies of immature CD34+/CD117+ cells compared to NOS-AMKL and AMKL-other.
- ML-DS patients exhibited a unique immunophenotypic profile with significantly higher expression of CD33, CD11b, CD38, and CD7.
Conclusions:
- The EuroFlow AML panel provides a straightforward method for diagnosing AMKL.
- Specific immunophenotypic markers can reliably differentiate AMKL subtypes.
- ML-DS is characterized by a distinct immunophenotypic signature, aiding in its identification.
